RaQualia PharmaTSE:4579 -2.70%57 Altman Z-Score is 2.93 as of Jul. 08, 2026, which is 90% below its 10-year median of 28.51. GuruFocus rates TSE:4579 with a GF Score™ of 57/100 and a GF Value™ of 円961.31 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 923 Biotechnology companies, RaQualia Pharma ranks better than 51.57% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 2.93 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
RaQualia Pharma has a Altman Z-Score of 2.93, indicating it is in Grey Zones. This implies that RaQualia Pharma is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for RaQualia Pharma's Altman Z-Score or its related term are showing as below:
TSE:4579'
s Altman Z-Score Range Over the Past 10 Years
Min: 1.65 Med: 28.51 Max: 163.16
Current: 2.93
During the past 13 years, RaQualia Pharma's highest Altman Z-Score was 163.16. The lowest was 1.65. And the median was 28.51.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
RaQualia Pharma Altman Z-Score Related Terms
RaQualia Pharma Altman Z-Score Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, RaQualia Pharma's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
RaQualia Pharma's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.4766
+
1.4
*
0.0002
+
3.3
*
-0.0355
+
0.6
*
3.7869
+
1.0
*
0.2052
=
2.93
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
RaQualia Pharma (TSE:4579) has a Altman Z-Score of 2.93 as of Jul. 08, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on RaQualia Pharma and its competitors. This is 90% below median its historical median of 28.51. Over the past decade, RaQualia Pharma's Altman Z-Score has ranged from 1.65 to 163.16. According to the industry distribution chart, RaQualia Pharma ranks #447 out of 923 companies in the Biotechnology industry, placing it in the top 48.4%.
Is RaQualia Pharma's Altman Z-Score too high?
RaQualia Pharma's current Altman Z-Score of 2.93 is 90% below median its 10-year median of 28.51. Over the past 10 years, this metric has ranged from a low of 1.65 to a high of 163.16. The Biotechnology industry median Altman Z-Score is 2.76. RaQualia Pharma's value of 2.93 is 6.2% above this industry median. Based on the distribution chart, RaQualia Pharma ranks #447 out of 923 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #447 out of 923 companies for Altman Z-Score. This puts RaQualia Pharma in the upper half of its industry. The industry median Altman Z-Score is 2.76. RaQualia Pharma's value of 2.93 is 6.2% above this benchmark. Historically, RaQualia Pharma's own Altman Z-Score has ranged from 1.65 to 163.16 over the past decade. While the company's 10-year median is 28.51 vs. the industry median of 2.76, RaQualia Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.76, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaQualia Pharma's current Altman Z-Score of 2.93 is 6.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current Altman Z-Score is 2.93, which is 90% below median its own 10-year median of 28.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current Altman Z-Score is 2.93, which is 90% below median its 10-year median of 28.51 and 6.2% above the Biotechnology industry median of 2.76. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Altman Z-Score is 2.93 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31.
GuruFocus considers RaQualia Pharma to be Significantly Undervalued.
Key valuation signals for TSE:4579:
Altman Z-Score: 2.93 (90% below median its 10-year median of 28.51)
GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
Industry Position: 6.2% above the Biotechnology median (#447 of 923)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score
Get the complete analysis for TSE:4579
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
